Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (January 2013)
35 slides from Fluoropharma Medical's investor presentation, Jan 2, 2013
Slide 1: Enabling Personalized Medicine by Making the Invisible, Visible
Flu@geyieae. =e Phaniina Enabling Personalized Medicine by Making the Invisible, Visible.
Slide 2: Forward-Looking Statements
Fluoro Forward-Looking Statements Pharma This presentation contains “forwarcHooking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Fluoro Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS, PATIENT MANAGEMENT Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Next generation molecular imaging drugs for diagnostic
Slide 4: Investment Highlights
Fluoro Investment Highlights. Pharma Proprietary products that support new technologies for personalized medicine ‘+ Next generation / firstin-class diagnostic imaging + Helps determine the course of cardiac treatment Two Phase Il-eady praducts with short study timelines, both directed to very large
Slide 5: The Next Big Step in Healthcare
Fluoro The Next Big Step in Healthc: 5 MEDICINE TODAY One treatment fits all - »> still a guessing game ‘wow. FluoroPharma.com
Slide 6: Personalized Diagnosis
Fluoro Personalized Diagno: Pha MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome ¥ Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis ‘wow. FluoroPharma.com
Slide 7: Unmet Need for Better Imaging Methods
Fluoro Unmet Need for Better Imaging Methods Pharma MRI FDA Warning in 2007 + Nephrogenic systemic fibrosis for Gadolinium-based contrastagents a = aren. ra FDA Warning in 2007 IMAGING > + Deaths and serious cardiopulmonary reactions arising from marketed products None of these capture 5 ots ia: Por
Slide 8: Growing Market for Imaging Agents
ge. Growing Market for Imaging Agents Fluoro Pharma *+ Global market projected to exceed $15 billion by 2015 + Fueled by need for personalized medicine * Additional drivers include: Growing volume of diagnostic examinations and equipment sales ‘Advanced imaging agents in development * Aging populati
Slide 9: PET Imaging Roots are in Oncology
Fluoro PET Imaging Roots are in Oncology Pharma PET procedures by disease area 2500 2000 Cardiology 1500 Aa) neurology remain 1000 strong growth ‘opportunities 500 a = 2008 2008 2008 2007 2008 Ea Year HH Oncology Ill Neurology lll Cardiology a Tae Fos asian 2008 ‘wow. FluoroPharma.com
Slide 10: Cardiovascular Disease is the Next Big Opportunity
Fluoro — Pharma Cardiovascular Disease is the Next Big Opportunity Total diagnostic radiopharmaceutical agents market Cardiac imaging procedures are the greatest opportunity to switch to PET Procedures bee 25 (millions) CAGR ‘07-09 PET (Total) 17.0% 15 SPECT (Cardiac) 7.3% 2 SPECT (Other) 5.3% Total
Slide 11: FluoroPharma Enables Personalized Diagnosis
Fluoro | Pharma FluoroPharma Enables Personalized Diagnosis Imaging provides non-invasive tools with immediate personalized recommendations for treatment + Allows direct visual evaluation of Mathod Utrasound 2 mm <10 ms + Measures the efficacy of treatment + Tracks response to theray ontinuing appro
Slide 12: Poised to Capture Cardio Diagnostics
Fluoro Poised to Capture Cardio Diagnostics Beara + Lin-3 adults have some form of CV + Superior image quality * $403 billion: fully burdened cost of imaging platform = + No widely adopted PET agents in Positioned to capture share of the $7 billion** marketfor molecular imaging agent ‘www FuoroPharm
Slide 13: Making the Invisible, Visible
Fluoro . Making the Invisible, Visible Pharma BFPET \VasoPET Formeasur y Fordetecting vascular b inflamed plaques + Forse in combination with + Modified fatty acia (MFA) + Avidly taken up by inflammatory stress-testingin patients with deisgned to optimize imaging cells and rapidly dividing cells oni
Slide 14: Robust Portfolio On-Track
Fluoro Robust Portfolio On-Track Pha Srore compet ures aes ectamareaen kent Patan taints neg Comet Soca Fania ip es Ne Canara a5 Conroe {Sem geerascocnee ots ees.» Prengepcatncongeoonnesiersndhstn ‘www. FluoroPharma.com
Slide 15: Product Portfolio Market Size and Revenue Opportunity
Fluoro Product Portfolio Market Size and Revenue Opportunity eearnial BFPET CardioP ET vvasoPET 120m a74m 355m ae 20.50% 30-50% 15% Adoption 3.660 528.1m 09m PETProcedures aS 40.90% 21-41% 100% Market Sha 1.45.4m 133.6m oom FPMI Prov FPMIPrice $600 $600 $600 Dose * $0.93.2B $0.82.2B $510M a ‘woww.Fl
Slide 16: BFPET Clinical Use
Fluoro BFPET Clinical Use Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (e.g MIBI, tetrophosmin, 1-201) or Rb-82
Slide 17: BFPET Phase I Trial Findings
Fluoro BFPET Phase | Trial Findings Pharma BFPET Pha naging propertie Rapid extraction from blood Stable heart uptake overtime + Noll sigcant changes noted HIG ie rr in follow-up clinical and laboratory + Whole body effective dose: 73. testing 17.59 mrem/mCi + 12 healthy volunteers ages 20-85 + No a
Slide 18: The BFPET Opportunity
Fluoro The BFPET Opportunity Pharma Projected BFPET Scans Assumpt uuions 14 Est. 5® Year Revenue. 2 $691 milion Est PET eel Mane Pas iaiker See os | Myocardial 08 perfusion 12min —_3.6milion imaging os} o2 — Yeord Year a. ‘wow. FluoroPharma.com
Slide 19: CardioPET Clinical Use
Fluoro CardioPET Clinical Use Pharma CARDIAC VIABILITY ASSESSMENT + Identify patients that may benefit from PC! or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT. + Invasive coronary angiography CLINICAL NEED + 13 million diagnostic angiogr
Slide 20: CardioPET Phase I Trial Results
CAD Subject Fatty acid analog that detects regions of metabolic insufficiency t r PHASE I TRIAL COMPLETED (15 NHV and 6 CAD patients) ithno AES + CardioPET promising safety detected + Clinical findings consistent with MP1 SPECT * Quality of CardioPET images substantially ‘Superior to MPI SPECT 26 mi
Slide 21: The CardioPET Opportunity
Fluoro The CardioPET Opportunity Ss Pharma Projected CardioPET Scans aon np Est. 5® Year Revenue $605 milion 16 Est. PET Est FP. ul Patients arketSize Share a2 CAD diagN0SS 5 5minon LA milion siet 38million —L1milion 32% 08 Cardiac viability aecesement, EOmilion O.5milion 80% 04 Myocardial As perfus
Slide 22: VasoPET Indications and Clinical Use
Fluoro VasoPET Indications and Clinical Use Pharma EVALUATION OF + Patients with acute cardiac eventoor stroke (isk of recurring event) + Therapy following acute cardiac event or stroke (e.g. Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE + Clinical symptoms; several imaging agen
Slide 23: Detection Of Inflamed Atherosclerotic Plaque
Fluoro | Detection Of Inflamed Atherosclerotic Plaque Pharma WHY INFLAMMATION IMAGING’ + Diagnosis before sym + Crucial role at all sta atherosclerosis + May aid drug development DEVELOPMENT STATUS + Preclinical testing completed + IND preparation ongoing + Pian to initiate Phase | proof of principl
Slide 24: The VasoPET Opportunity
Fluoro The VasoPET Opportunity Paria Projected VasoPET Scans sauions impli ae Est. 58 Year Revenue 07 $408 milion 06 Est. PETMkt 05 Market Patients ce Screening for ce emugening'or, 50milion 300,000 na Responseto 02 tnerapy(stauns) 22min 380,000 o Followup after 0 0.9milion 90,000 heart attack Yearl
Slide 25: Targets Greatest Areas for Cost Reduction
Fluoro Targets Greatest Areas for Cost Reduction Pharma ‘Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of hea
Slide 26: Experienced Management Team and Advisors
Fluoro Experienced Mana Team and Advisors Barina Thijs Spoor President, CEO + Heattncare executive wth >45 years medical industry experience * Former secuttes ast at P Morgan and Cre Suisse covering the medica devoe and Dotechrobgy ingustnies + Previous lea the nvler cardiology pototo and PET new pr
Slide 27: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Fluoro Pharma Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment ‘+ Myocardial perfusion imaging + Infiamed atherosclerotic plaque imaging ‘Address unmet needs in cardiovascular diagnostics by providing * Diagn
Slide 28: Slide 28
Slide 29: Multiple players in each value chain
Radio Pharmaceutical Distribution Molecular Eckert & Ziegler ardinal Health ovidien Philips Development ‘Multiple players in each value chain ‘wow. FluoroPharma.com
Slide 30: The cycle of classic medicine is reactive medical care
Fluoro The cycle of classic medicine is reactive medical care eearnial Reactive Medical Care h Drug Again went Switch Drug. sa Select rie Dee Time Diagnose Disease: Treat Symptoms: Costly, Trial and Error Treatment a Fesaraaes Wodons Gotan sans PeSSTaRaT ‘wow. FluoroPharma.com
Slide 31: Shifting to outcomes and efficiency
Fluoro Shifting to o s efficiency Eman Efficient Medical Care Right Drug Disease Seventy Diagnosis / Prognosis Health Management: Molecular Screening: Early Detection: Rapid Effective Treatment: Improved Quality of Care ‘wow. FluoroPharma.com a Panna
Slide 32: US and WW Cardiovascular Disease Epidemic
US AND WW ted Global Epidemic’ + 16.7M deaths WW: 1/3 of all deaths, 78% from iow / middle income count of deaths in China, ¥2in Europe + 2.4M deaths US: top c KEY UNMET NEEDS, ‘+ CAD: Get closer to the disease source ~ Early detection & appropriate treatment selection + AML: Identify vulnerable pat
Slide 33: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints Fluoro Pharma Economic pressures past FUTURE ne a a a a a eo nonsystems > systemsof ofcare care celvery (Domentonal I) GomplexMutsakonoler nee aE edi rope Eeicaesce SS , selopredoners _(etiniidulpreibos_ coma nutri a ADs type ‘retain significant a
Slide 34: Market Drivers for New PET Products
Market Drivers for New PET Products Fluoro . Pharma Growth in PET dural volumes PET Prove Past PET Mar t pacity utilization comprehensive adoption of early diagnosis will improve utilization of technology on diagnosed e outcomes pacity, more patients could be ier leading to better patient + Ealier d
Slide 35: Thank you for listening!
Flu@geyieae. =e Phaniina Thank you for listening!
FluoroPharma Medical — Investor Presentation (January 2013) on 6ix